Skip to Content
Merck
  • Pathogenic variants in the human m6A reader YTHDC2 are associated with primary ovarian insufficiency.

Pathogenic variants in the human m6A reader YTHDC2 are associated with primary ovarian insufficiency.

JCI insight (2022-02-10)
Sinéad M McGlacken-Byrne, Ignacio Del Valle, Polona Le Quesne Stabej, Laura Bellutti, Luz Garcia-Alonso, Louise A Ocaka, Miho Ishida, Jenifer P Suntharalingham, Andrey Gagunashvili, Olumide K Ogunbiyi, Talisa Mistry, Federica Buonocore, Berta Crespo, Nadjeda Moreno, Paola Niola, Tony Brooks, Caroline E Brain, Mehul T Dattani, Daniel Kelberman, Roser Vento-Tormo, Carlos F Lagos, Gabriel Livera, Gerard S Conway, John C Achermann
ABSTRACT

Primary ovarian insufficiency (POI) affects 1% of women and carries significant medical and psychosocial sequelae. Approximately 10% of POI has a defined genetic cause, with most implicated genes relating to biological processes involved in early fetal ovary development and function. Recently, Ythdc2, an RNA helicase and N6-methyladenosine reader, has emerged as a regulator of meiosis in mice. Here, we describe homozygous pathogenic variants in YTHDC2 in 3 women with early-onset POI from 2 families: c. 2567C>G, p.P856R in the helicase-associated (HA2) domain and c.1129G>T, p.E377*. We demonstrated that YTHDC2 is expressed in the developing human fetal ovary and is upregulated in meiotic germ cells, together with related meiosis-associated factors. The p.P856R variant resulted in a less flexible protein that likely disrupted downstream conformational kinetics of the HA2 domain, whereas the p.E377* variant truncated the helicase core. Taken together, our results reveal that YTHDC2 is a key regulator of meiosis in humans and pathogenic variants within this gene are associated with POI.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-YTHDC2 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution